This was a phase 3, randomized, double-blind, placebo-controlled study to evaluate an investigational medication in subjects with type 2 diabetes mellitus who are not adequately controlled by metformin alone.
The medication belongs to a class of diabetic medication called SGLT2 inhibitors. SGLT2 inhibitors lower blood sugar by causing the kidneys to remove sugar from the body through the urine. The calories that are lost in the excreted glucose in the urine may help with weight reduction that could benefit many subjects with Type 2 diabetes mellitus (T2DM).
About 350 subjects in the United States and Japan participated in this study.